Results 11 to 20 of about 44,755 (247)
Abstract Background Bevacizumab—a humanized monoclonal antibody—has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet been conducted. Methods This study is a double‐blind multicenter randomized phase 2 trial with a 1:1 active‐treatment‐to‐placebo ratio. We included patients over the age
Sophie Dupuis‐Girod +25 more
wiley +1 more source
Background – The caninised monoclonal antibody lokivetmab (LKV), directed at interleukin (IL)‐31, is very effective at controlling pruritus in most dogs with atopic dermatitis (AD). However, evidence exists that IL‐31 is not required for the induction of acute allergic skin inflammation, which might explain why this treatment is less efficacious in ...
Chie Tamamoto‐Mochizuki +4 more
wiley +1 more source
LncRNA HOTAIR exhibited different effects in human cancers. However, the role of HOTAIR was not reported in osteosarcoma. This study aimed to explore the function of HOTAIR in osteosarcoma. Firstly, we examined HOTAIR expression in breast cancer tissues by the RT‐qPCR assay and examined HOTAIR protein expression via immunocytochemistry, to chemical ...
Hang Li +3 more
wiley +1 more source
Hsa_circ_0001666 suppresses the progression of colorectal cancer through the miR‐576‐5p/PCDH10 axis
This study demonstrates that hsa_circ_0001666 suppresses the progression of colorectal cancer. Hsa_circ_0001666 can regulate the PCDH10 expression by competitively interacting with miR‐576‐5p. Hsa_circ_0001666 inhibits the Wnt/β‐catenin signalling pathway.
Jiahui Zhou +12 more
wiley +1 more source
Anticorps thérapeutiques [PDF]
Monoclonal antibodies and their derivatives such as antibody fragments, immunoconjugates and Fc fusions, represent the majority of therapeutic proteins in clinical development. Recent successes of such molecules in cancer and in the treatment of autoimmune diseases found a great hope in biotherapeutics.
Lucie Manache +2 more
openaire +1 more source
Background – Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. Hypothesis/Objectives – To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs.
Leen Van Brussel +4 more
wiley +1 more source
Immunopathogenesis of the feline atopic syndrome
Résumé Contexte Les maladies félines supposées d’origine allergique avec des phénotypes cliniques semblables, peuvent avoir de nombreuses pathogénies différentes sous jacentes. Le phénotype clinque, l’étiologie précise et l’immunopathogénie sous jacente doivent tous être considérés si des avancées veulent être faites dans ces domaines négligés de la ...
Richard Halliwell +3 more
wiley +1 more source
Guide pratique à l’intention des laboratoires cliniques pour les tests de sérologie du SRAS-CoV-2
Le répertoire des tests de diagnostic disponibles du coronavirus du syndrome respiratoire aigu sévère 2 (SRAS-CoV-2) évolue rapidement. Bien que les tests sérologiques aient une capacité de diagnostic limitée concernant l’infection aiguë, leur rôle dans ...
Carmen Charlton +20 more
doaj +1 more source
Differentiation of peanut clump virus serotypes by monoclonal antibodies [PDF]
Des anticorps monoclonaux dirigés contre le virus du "clump" de l'arachide ont permis de caractériser 5 sérotypes du virus. La comparaison de 4 types de tests immunoenzymatiques ELISA a permis de sélectionner celui qui est le mieux adapté au diagnostic ...
Givord, Louise +3 more
core +1 more source
Prevalence of antibodies against Babesia canis in dogs in an endemic area
Une recherche des anticorps contre Babesia canis, par le test ELISA, portant sur 287 chiens d'une zone endémique, a révélé une prévalence de 43 p. 100.
P.A. Bobade, O.O. Oduye, H.O. Aghomo
doaj +1 more source

